Thomsen-Friedenreich Antigen / CD176 (Pan Carcinoma Marker) Antibody - With BSA and Azide
Mouse Monoclonal Antibody [Clone A68-B/A11 ]
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application
| IHC, IF |
---|---|
Reactivity | Human, Mouse, Rat |
Host | Mouse |
Clonality | Monoclonal |
Isotype | Mouse / IgM, kappa |
Clone Names | A68-B/A11 |
Calculated MW | Multiple KDa |
Storage | Store at 2 to 8°C.Antibody is stable for 24 months. |
---|---|
Precautions | Thomsen-Friedenreich Antigen / CD176 (Pan Carcinoma Marker) Antibody - With BSA and Azide is for research use only and not for use in diagnostic or therapeutic procedures. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
Recognizes a disaccharide epitope, Gal1-3GalNAc, of Thomsen-Friedenreich (TF) antigen. It is specific for both anomeric forms of the disaccharide (TF and TF, including related structures on the glycolipid) and shows no cross-reactivity with sialylated glycophorin. The Thomsen-Friedenreich antigen acts as an oncofetal antigen, with low expression in normal adult tissues but increasing to fetal levels of expression in hyperplasia or malignancy. It is considered as a pan-carcinoma marker. This MAb is capable to agglutinate desialylated red blood cells. During metastasis, the ability of malignant cells to form multicellular aggregates via homotypic or heterotypic aggregation and their adhesion to the endothelium are critical. The tumor-associated carbohydrate Thomsen-Friedenreich antigen (Gal-GalNAc) is involved in tumor cell adhesion and tissue invasion. It also causes an immune response, and overexpression of the antigen causes cancer cells to be more sensitive to natural killer cell lysis. The Thomsen-Friedenreich antigen is suppressed in normal healthy cells and represents one of the few chemically well-defined antigens associated with tumor malignancy. The presence of the Thomsen-Friedenreich antigen on the surface of cancer cells may result from a divergence from the normal pathway for O-linked glycosylation in these cells, most likely caused by inappropriate localization of the enzymes involved in synthesis of the disaccharide.
References
Karsten U. 2002. CD176 Workshop panel report. In: Mason D, Simmons D, Buckley C, Schwartz-Albiez R, Hadam M, Saalmuller A, Clark E, Malavasi F, Morrissey JA, Vivier E, et al., editors. Leucocyte Typing VII. Oxford, UK: Oxford University Press. | Henderson G. et al. Glycobiology 21(10), 1277–1289 (2011
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.